Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren, Vincent Woo, Oluf Hansen, Anders G Holst, Jonas Pettersson, Tina Vilsbøll

November 2016 N Engl J Med

Synopsis of Social media discussions

Discussions consistently praise the robust evidence from trials like SUSTAIN-6 and Pioneer 6, exemplified by statements such as 'semaglutide reduces CV events by 20%' and 'shows real positive benefits.' The use of technical terms and references to specific studies demonstrates deep engagement and underscores the high impact of the findings on medical practice.

A
Agreement
 Strong agreement

Most discussions highlight the positive cardiovascular outcomes associated with semaglutide, showing strong support for its benefits.

I
Interest
 High level of interest

The discussions demonstrate high interest through mention of detailed study results, side effects, and potential implications for treatment.

E
Engagement
 High engagement

Many posters reference specific trials, statistics, and mechanisms, indicating deep engagement with the research.

I
Impact
 High level of impact

The overall tone emphasizes semaglutide’s significant potential to influence treatment guidelines and improve patient outcomes.

Social Mentions

YouTube

10 Videos

Bluesky

2 Posts

Facebook

29 Posts

Twitter

239 Posts

Blogs

21 Articles

News

141 Articles

Reddit

2 Posts

Metrics

Video Views

110,090

Total Likes

3,351

Extended Reach

3,063,170

Social Features

444

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

Understanding GLP-1 Medications for Type 2 Diabetes

Understanding GLP-1 Medications for Type 2 Diabetes

Ever wonder about medications like Trulicity, Ozempic, or Victoza? This video discusses the role of GLP-1 in managing blood glucose levels, how these medications function, their benefits, and potential side effects. Learn about their impact on Type 2 Diabetes management.

Sugar High

April 30, 2020

93,306 views

Ozempic causes weight loss. Does it cause hair loss?

Ozempic causes weight loss. Does it cause hair loss?

Haircafe

June 1, 2023

8,126 views

Impact of Ozempic, Wegovy, and Mounjaro on Body Composition

Impact of Ozempic, Wegovy, and Mounjaro on Body Composition

This video analyzes the impact of Ozempic, Wegovy, and Mounjaro on body composition. These GLP-1 receptor agonists have shown impressive efficacy in weight loss and altering body composition in individuals with type 2 diabetes. Discover their safety and effects on performance.

FalaLu!

September 1, 2025

6,561 views

Quantos quilos se perde com o Ozempic?

Quantos quilos se perde com o Ozempic?

Sávio Veríssimo

September 7, 2025

830 views

Current Advances in Atrial Fibrillation Treatment and Endurance Athlete Cardiac Risks

Current Advances in Atrial Fibrillation Treatment and Endurance Athlete Cardiac Risks

This week in cardiology discusses the VENTOUX study on endurance athletes and arrhythmias, the ongoing debate between rate and rhythm control in atrial fibrillation, and the role of GLP1 drugs. The importance of anticoagulation in stroke prevention is also highlighted.

Medscape

July 25, 2025

536 views

Impact of Ozempic on Eye Health Explained

Impact of Ozempic on Eye Health Explained

Can Ozempic affect eye health? In this video, Dr. Abdul Rasheed discusses potential ocular effects associated with Ozempic, including risks of blurry vision and nonarteritic anterior ischemic optic neuropathy (NAION). Learn about key studies and health tips related to Ozempic.

Dr Abdul Rasheed

September 25, 2025

461 views

Impact of Canagliflozin on Cardiovascular and Kidney Health in Type 2 Diabetes

Impact of Canagliflozin on Cardiovascular and Kidney Health in Type 2 Diabetes

Huge improvements in treatments for type 2 diabetes are outlined in recent diabetes guidelines. This video discusses the effectiveness of canagliflozin in significantly reducing major cardiovascular events and kidney-related issues compared to placebo.

Medscape

February 25, 2025

197 views

Effectiveness of DOACs in Atrial Fibrillation Management

Effectiveness of DOACs in Atrial Fibrillation Management

This week’s podcast reviews significant trials including NOAH-AFNET 6 and ARTESiA that highlight the role of direct oral anticoagulants (DOACs) in preventing ischemic stroke among patients with device-detected atrial fibrillation. Explore the implications for clinical practice.

Medscape

March 27, 2024

39 views

Ozempic and Semaglutide: Effects, Risks, and Future of Weight Loss

Ozempic and Semaglutide: Effects, Risks, and Future of Weight Loss

In this video, I break down what Ozempic semaglutide really does and its impact on health, including antiaging and fat-burning effects. We explore side effects like pancreatitis and retinopathy, plus future treatments such as myostatin inhibitors for muscle preservation.

Divya Datta

August 14, 2025

23 views

Semaglutide's Cardiovascular Safety and Effects in Type 2 Diabetes

Semaglutide's Cardiovascular Safety and Effects in Type 2 Diabetes

This week in cardiology, we discuss coronary CTA, semaglutide for type 2 diabetes, and upcoming cardiology events. Semaglutide showed cardiovascular benefits in a recent study, but requires monitoring for retinopathy risks.

Medscape

March 27, 2024

14 views

  • Bookdasa
    @Totoro19514032 (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 30, 2025

    42

  • Ahmed Al-Za'abi
    @AhZabi (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 27, 2025

    42

  • JJ
    @jjogodsz (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • Sovichia@789
    @Sovichia1993 (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • Syed Shahrul Naz
    @drshahrul80 (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • imran robleh
    @imran_rob (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • Gary Deed
    @garydeed (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • jorge gamboa
    @jorgega62811906 (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • MetaboliccareToday.com
    @MetabolicCare (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • Victor De La Espriella Badel
    @vimadelaeb (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • ResearchPulse
    @ResearchPulse1 (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • Sharona Azriel
    @SharonaAzriel (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • Wimen
    @1a31551c566e43d (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • abhimanyu singh
    @SardarAbhimanyu (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • Frankie
    @pacovelascor (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • Sayantan Mukherjee
    @hopelessweirdo (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • Abdulmohsen bakhsh د .عبدالمحسن بخش
    @amohsenbakhsh (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • Yanamandra Sastri
    @Yanamandra70982 (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • moath saleh
    @moathsaleh (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • JOON T
    @TubuloToxic (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 24, 2025

    42

  • Jamie Wang
    @jamiewang1228 (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • araceli miranda
    @amiraveg (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Niranjan Ganesh
    @Drniran (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Carolina Glz Fuentes
    @karolas_smile (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Abhishek
    @aksrulz13 (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Jorge Luis Rodríguez .
    @JL____Rodriguez (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • MaFer Zavala
    @Mafer_ZavalaM (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Chih-Yao Hsu
    @reclast (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Roberto Gutiérrez
    @DrRobertoGuti (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Katty Rivera
    @KattyRiveraG (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Dr Jorge Ferradas Solar
    @JorgeFerradasSo (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Serigne_Fall
    @fallserigne34 (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Joyce Bwombengi
    @kemuntoMD (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Kidneyman
    @Kidneyman5 (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Layla Omar
    @hlaylaomar (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Gabriel D.C.
    @GabDavC (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • 木下卓哉
    @tSMAJ2uzxBX1hoH (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Joel M. Topf, MD FACP
    @kidney_boy (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Ye M. Tun, MD FACP
    @DrYeMyintTun (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Anjana Gopal, MBBS, MD, DM Nephrology, FASN
    @AnjanaGopal9 (Twitter)

    RT @edgarvlermamd: Effects of Once-Weekly
    view full post

    October 23, 2025

    42

  • Edgar V. Lerma
    @edgarvlermamd (Twitter)

    Effects of Once-Weekly
    view full post

    October 23, 2025

    113

    42

  • Edgar V. Lerma
    @edgarvlermamd.bsky.social (Bluesky)

    Effects of Once-Weekly Semaglutide #Nephpearls #Cardiorenal #NephSky
    view full post

    October 23, 2025

    2

  • Edgar V. Lerma
    @edgarvlermamd (Twitter)

    Effects of Once-Weekly Semaglutide #Nephpearls #Cardiorenal #VisualAbstract by @AnjanaGopal9 @kidney_boy @brian_rifkin FLOW
    view full post

    October 23, 2025

    1

  • Phòng Khám MedFit
    @PhongKhamMedFit (Twitter)

    Marso SP, Bain SC, et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes“. N Engl J Med. 2016;375(19):1834-1844. - https://t.co/dygefqG1rI
    view full post

    September 8, 2025

  • David Ramírez Saco
    @DRami15 (Twitter)

    RETINOPATÍA DIABÉTICA (1/2) ❌ - La noticia la menciona como complicación, pero el prospecto habla de EMPEORAMIENTO si RD previa + insulina - Hallazgo en ensayo de no-inferioridad de resultados
    view full post

    August 21, 2025

  • Apurva Patel MD, FACC, FSCAI, RPVI
    @patelapurva (Twitter)

    @tehseenp Yes there are side effects and needs to be monitored closely. https://t.co/n1I3JXUtWs https://t.co/r508EbK1xT https://t.co/ickuubZa43
    view full post

    June 30, 2025

    2

  • おだQ
    @OdaQ_DM (Twitter)

    PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11. PMID: 31185157. https://t.co/DcznGmn23E
    view full post

    May 8, 2025

    3

  • NEJM Journal Watch
    @JWatch (Twitter)

    NEJM Group’s Dr. Lauren Westafer talks with Dr. Darren McGuire about his group’s trial on oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes who have increased cardiovascular risk. https://t.co/c5nEtE3bfG #ACC25 @LWestafer https://t.co/GsIavbfNYG
    view full post

    March 31, 2025

    4

  • Jikkyleaks
    @Jikkyleaks (Twitter)

    @MaelstromCap @kevinnbass "Rates of retinopathy complications (vitreous hemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation) were significantly higher (hazard ratio, 1.76)... " What a great drug. You read your study yeah? https://t.co/bjviNF0SiT
    view full post

    December 5, 2024

    2

  • m
    @_grapejulce (Twitter)

    @jsjr0313 @mqyxf @memeticsisyphus semaglutide* is a GLP1 analogue, “semaglutides” are not a thing. It has been proven by clinical studies to improve cardiovascular outcomes. Not saying you shouldn’t exercise if you use it of course. But you’re not right. https://t.co/ehIOfGujxv
    view full post

    December 1, 2024

  • Dogs&Viruses
    @Craigster771 (Twitter)

    @UrgentKarr @jackmurphylive @FitFounder How about you read the cardiovascular outcomes studies in actual humans (non-diabetics and diabetics)? https://t.co/2QfrIf22at https://t.co/34DfC0vd8h
    view full post

    November 21, 2024

  • Dogs&Viruses
    @Craigster771 (Twitter)

    @FitFounder Link to actual human studies: In diabetics: https://t.co/34DfC0vd8h In non-diabetics: https://t.co/2QfrIf22at
    view full post

    November 21, 2024

    1

  • shaffy
    @shaffy8585 (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    November 14, 2024

    100

  • VeeJayDont
    @VeeJayDo2 (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 26, 2024

    100

  • Logos2021 Centrist, XX, Pro-Free Speech
    @LogosMMXX (Twitter)

    @fivehundredpou1 @MdBreathe Lots that needs to change. Concerned with emphasis on pharmacological solutions only. Need longer study of GLP-1s. The reductions (.3/100 for stroke, for ex) don't justify the massive push. Cardiovascular: https://t.co/8tk1ghNpxa Stroke: https://t.co/jkCXDO6v6u https://t.co/lUOh5XMfCf
    view full post

    September 1, 2024

  • Roots Community Health
    @RootsEmpowers (Twitter)

    Links Included in Briefing: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes: https://t.co/rqX4giyteM Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: https://t.co/6mmrAYKPp7
    view full post

    August 6, 2024

  • REC Publications
    @RevEspCardiol (Twitter)

    Once weekly semaglutide and cardiovascular outcomes in patients with type 2 diabetes and heart failure with reduced left ventricular ejection fraction #REC https://t.co/nTQB1Hg3c2
    view full post

    July 22, 2024

  • こたつDr
    @drkotatsu (Twitter)

    https://t.co/iKUZXlq85n SUSTAIN6 での解析でも 腎症の新規発症率、悪化率はセマグルチド群で有意に低いのに、網膜症に関連した合併症の発生率は、セマグルチド群で有意に多く認めらた（3.0％ vs. 1.8%, ハザード比:1.76, 95％CI : 1.11～2.78、P＝0.02） これに関しては別試験で検証中とは思われる https://t.co/rTkczzXcPU
    view full post

    July 5, 2024

    3

  • Kariova
    @pKariova (Twitter)

    RT @joaumdoistres: Como sempre, os leigos falam do que não entendem e comparam ozempic com anabolizantes. Semaglutida reduz em 20% o risco…
    view full post

    April 20, 2024

    1

  • degustador de microplásticos
    @joaumdoistres (Twitter)

    Como sempre, os leigos falam do que não entendem e comparam ozempic com anabolizantes. Semaglutida reduz em 20% o risco cardiovascular em não-diabéticos (https://t.co/LLXCjvBjC7) e 26% em diabéticos (https://t.co/JaZf1zneSW) https://t.co/TxPQqef8UV
    view full post

    April 20, 2024

    37

    1

  • HMPerson1
    @HMPerson1 (Twitter)

    @hankgreen the articles that these graphs are from, for reference: https://t.co/IYDA1Vl2U9 https://t.co/7tCNxdabSR
    view full post

    March 17, 2024

    1

  • Juanmarcosgg
    @juanmarcosgg (Twitter)

    RT @RevEspCardiol: Once weekly semaglutide and cardiovascular outcomes in patients with type 2 diabetes and heart failure with reduced left…
    view full post

    February 6, 2024

    1

  • REC Publications
    @RevEspCardiol (Twitter)

    Once weekly semaglutide and cardiovascular outcomes in patients with type 2 diabetes and heart failure with reduced left ventricular ejection fraction #REC #AOP @belmonte_dr @InfoUMA @_ibima @HRegionalMalaga @CIBER_CV @RGomezHuelgas @MRBernalLopez https://t.co/5CPksDZu7y
    view full post

    February 6, 2024

    3

    1

  • Nicholas Kaknes
    @NickKaknes (Twitter)

    @zfawx0 @QuisitiveInvest https://t.co/Lj7ekVtKyb
    view full post

    December 23, 2023

    1

  • Nhio Matambo
    @DrMats29 (Twitter)

    SEMAGLUTIDE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES (SUSTAIN-6 TRIAL) https://t.co/XfJZ9lq6a5
    view full post

    December 21, 2023

  • Beverly G. Tchang, MD
    @BevTchangMD (Twitter)

    @a_h_ghoneem (Background: #Ozempic ❤️ protection driven by nonfatal stroke, https://t.co/JBa1526kWi whereas liraglutide's was driven by fatal MI, https://t.co/1IWK2n9HHX ) 6/ https://t.co/XDOlj5m20y
    view full post

    December 3, 2023

    1

  • Dr.U@糖尿病メモ
    @dr_ukio (Twitter)

    SUSTAIN-6でセマグルチド群で網膜症増加したことを受けてのメタ解析。 https://t.co/aSTsMP9lwv https://t.co/1ZgBrfdrCN https://t.co/G13jDz2Dav
    view full post

    December 1, 2023

    1

  • Professor M Z Khalil
    @mzkhalil (Twitter)

    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DM | NEJM The rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving #semaglutide https://t.co/z9ikways5K https://t.co/fZDuM3kWqh
    view full post

    November 15, 2023

    1

  • M Azfar Qureshi
    @MAQ_Renal (Twitter)

    RT @kidney_boy: Here are the adverse events from SUSTAIN-6. Balanced SAEs and no signal for pancreatitis. https://t.co/4lX3PyIqO5 https://…
    view full post

    October 12, 2023

    3

  • Dr Anastasia Mihailidou FAHA FCSANZ FESC
    @AnastasiaSMihai (Twitter)

    RT @kidney_boy: Here are the adverse events from SUSTAIN-6. Balanced SAEs and no signal for pancreatitis. https://t.co/4lX3PyIqO5 https://…
    view full post

    October 12, 2023

    3

  • Joel Topf
    @kidneyboy.bsky.social (Bluesky)

    Here are the adverse events from SUSTAIN-6. Balanced SAEs and no signal for pancreatitis. https://www.nejm.org/doi/10.1056/NEJMoa1607141
    view full post

    October 12, 2023

    1

  • Joel M. Topf, MD FACP
    @kidney_boy (Twitter)

    Here are the adverse events from SUSTAIN-6. Balanced SAEs and no signal for pancreatitis. https://t.co/4lX3PyIqO5 https://t.co/wUFB2GziHR
    view full post

    October 12, 2023

    9

    3

  • Masato Nakazawa, Confidence Rebuilder
    @arafif_hubbie (Twitter)

    This randomized, double-blind, placebo controlled study was published in New England Journal of Medicine in 2016. 3/3 original article: https://t.co/v0bev3g5Yn
    view full post

    September 21, 2023

  • Theophan the Recluse Fan
    @LowStudies (Twitter)

    @DanielJDrucker @CaloriesProper @jerryteixeira @sguyenet @gerdosi @garytaubes @DrEades @davidludwigmd The long form of the study. https://t.co/2Ur41odcp4
    view full post

    September 7, 2023

  • Mind Your Science!
    @MindYourSci (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 22, 2023

    16

  • Un-nudgeable
    @KPlorable (Twitter)

    @KaladinFree Ozempic is good for the heart. Maybe trump should be considering. https://t.co/P9rSgxo3nA
    view full post

    August 21, 2023

    3

  • Zaher Toumi MD
    @ZaherToumi (Twitter)

    RT @DrKarlNadolsky: @ZaherToumi C/w the trials! https://t.co/2VbOrrthMQ https://t.co/caxaVY7wny
    view full post

    August 20, 2023

    1

  • Karl Nadolsky
    @DrKarlNadolsky (Twitter)

    @ZaherToumi C/w the trials! https://t.co/2VbOrrthMQ https://t.co/caxaVY7wny
    view full post

    August 20, 2023

    1

    1

  • Karl Nadolsky
    @DrKarlNadolsky (Twitter)

    @MichaelAlbertMD @DrNadolsky From cvot & meta-analyses this is pretty consistent https://t.co/caxaVY7wny https://t.co/2VbOrrthMQ
    view full post

    August 20, 2023

    1

  • ガラパゴス伊藤@総合診療医
    @galapagos_ito (Twitter)

    セマグルチドのエビデンス調べてるんですが、ちょっとよくわかんなくて困ってます。 セマグルチドが0.5mgでも1mgでもどっちでもいいのか知りたいんですが、本文中は0.5mg+1mgではPrimary outcomesは有意差あるけど、Appendixでは0.5mgも1mgも有意差ないんですがなぜですか？ https://t.co/u1XzHtoWik https://t.co/w1j8E52flf
    view full post

    August 17, 2023

    2

  • Dr.Lama Amer, MD
    @Dr_Lama_Amer (Twitter)

    In a recent meta-analysis there was a 17% reduction in fatal and non-fatal stroke #Semaglutide leads the pack with 35% reduced stroke risk in the SUSTAIN-6 trial مراجع الدراسات: https://t.co/7zFn1W6jCz https://t.co/18vqYp03EK https://t.co/B6a04XEJBc
    view full post

    August 13, 2023

  • Dr Gail Ashford
    @drgail3 (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 10, 2023

    16

  • Kaushal Kashyap Ⓥ
    @ktimesk (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 9, 2023

    16

  • Uku Vainik
    @ukuv (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 9, 2023

    16

  • Jose C Souto, MD
    @jcsouto (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 9, 2023

    16

  • Aljosa Kuzmanovski
    @Aljoo5 (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 9, 2023

    16

  • Hugo Viegas
    @HugoViegas_17 (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 9, 2023

    16

  • Thomas Pinnock
    @Thomas_Pinnock_ (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 9, 2023

    16

  • Mary Lewis
    @mem_lewis (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 8, 2023

    16

  • Christian Tams MS RD LDN
    @ChristianTams (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 8, 2023

    16

  • Chase Campbell
    @ChaseCa33292073 (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 8, 2023

    16

  • Brock Golfs
    @BrockGolfs (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 8, 2023

    16

  • Aaron Lepeska
    @AaronLepeska (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 8, 2023

    16

  • Pere Joan Sala
    @Fradbius (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 8, 2023

    16

  • Kurt Harris MD
    @radfugee (Twitter)

    RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…
    view full post

    August 8, 2023

    16

  • Stephan J. Guyenet
    @sguyenet (Twitter)

    Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. Context: This is the third RCT to show CV event reduction with sema. https://t.co/1gvqimJ3Hm https://t.co/oTQfAhNe79 https://t.co/dLsjoqY7Ns
    view full post

    August 8, 2023

    49

    16

  • Ethan J. Weiss
    @ethanjweiss (Twitter)

    Should have included reference to both Sustain-6 https://t.co/Ims4Mg8ukC and LEADER: https://t.co/7TgR0eLuLu
    view full post

    August 8, 2023

    3

  • Ethan J. Weiss
    @ethanjweiss (Twitter)

    @matthewherper It is really that surprising based on these results? https://t.co/7TgR0eLuLu https://t.co/Ims4Mg8ukC
    view full post

    August 8, 2023

    3

  • Nutty Buddy
    @NuttyBuddy9 (Twitter)

    RT @CMichaelGibson: These data in non-diabetics, builds upon previously published data in diabetics showing a 26% reduction in cardiovascul…
    view full post

    August 8, 2023

    1

  • Carl-Magnus Hake
    @CM_Hake (Twitter)

    ... typ 2-diabetes som är en rejäl riskfaktor, om än att de var större (96,7 kg i snittingångsvikt mot 92,1 kg i Sustain-6) och fick en högre dos semaglutid. Läs mer om Sustain-6 här: https://t.co/iXXzc721dX
    view full post

    August 8, 2023

  • Rumpel Style
    @Rumpel (Twitter)

    @ThierryBorgeat Die Daten sind wissenschaftlich nix neues. Die relative Risikoreduktion für vaskuläre Ereignisse unter Semaglutid liegt bei 20-30%. Der Effekt ist nicht dosisabhängig (schon 2016: https://t.co/zkc95epc7o). Neue Indikation führt aber zu neuem Patentschutz im jeweiligen Bereich.
    view full post

    August 8, 2023

  • C. Michael Gibson MD
    @CMichaelGibson (Twitter)

    These data in non-diabetics, builds upon previously published data in diabetics showing a 26% reduction in cardiovascular outcomes https://t.co/WIQ8vsok1B https://t.co/CmjwKWh8O8
    view full post

    August 8, 2023

    4

    1

  • Stephan J. Guyenet
    @sguyenet (Twitter)

    @DrRyanPDaly @MichaelAlbertMD There's already evidence that semaglutide reduces cardiovascular events comparably to statins in people with T2DM. https://t.co/oTQfAhNe79 https://t.co/dLsjoqY7Ns
    view full post

    August 2, 2023

    8

  • Alice
    @AliceFromQueens (Twitter)

    @b01dface https://t.co/elfdtzn88p
    view full post

    June 28, 2023

  • BiotechObserver
    @BiotechObserver (Twitter)

    @guy84179559 @Citrini7 @KlendathuCap It would seem not. https://t.co/IPxACNu8Jd
    view full post

    June 26, 2023

  • S
    @sssaoirseee (Twitter)

    RT @raphaels7: * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placeb…
    view full post

    May 27, 2023

    6

  • DrV
    @DrVasquezHealth (Twitter)

    RT @raphaels7: * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placeb…
    view full post

    May 27, 2023

    6

  • JohnWashington
    @JW09173474 (Twitter)

    RT @raphaels7: * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placeb…
    view full post

    May 26, 2023

    6

  • Dale, The Data Obsessed Fat Guy
    @DOFGuy (Twitter)

    RT @raphaels7: * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placeb…
    view full post

    May 26, 2023

    6


  • @colormesheesh (Twitter)

    RT @raphaels7: * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placeb…
    view full post

    May 26, 2023

    6

  • Citizen of EU
    @wavetossed (Twitter)

    RT @raphaels7: * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placeb…
    view full post

    May 26, 2023

    6

  • Raphael Sirtoli
    @raphaels7 (Twitter)

    * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placebo group's https://t.co/TAgV1dYiJp (Table S10) 0.5mg semaglutide⬆️2 BPM, so 2.5mg semaglutide may⬆️> 4-5 bpm "resting heart rate is a predictor of
    view full post

    May 26, 2023

    61

    6

  • Alaa (آلاء) Alarbash
    @3A3Dr (Twitter)

    RT @Dr_Lama_Amer: @Abo_Yasser1993 تفضل المصادر https://t.co/LntZ4TNeoy https://t.co/RmphgdzT1M https://t.co/taxi9jL0En https://t.co/7z…
    view full post

    April 30, 2023

    1

  • Dr.Lama Amer, MD
    @Dr_Lama_Amer (Twitter)

    @Abo_Yasser1993 تفضل المصادر https://t.co/LntZ4TNeoy https://t.co/RmphgdzT1M https://t.co/taxi9jL0En https://t.co/7zFn1W6jCz https://t.co/uDzI9HjNLc
    view full post

    April 30, 2023

    18

    1

  • Beverly G. Tchang, MD
    @BevTchangMD (Twitter)

    And we have the SUSTAIN-6 CVOT for semaglutide 1.0 (Ozempic) but not sema 2.4 (Wegovy), which showed #CVD benefit driven by a ↓ in stroke https://t.co/Ipe1CLssj1 3/
    view full post

    January 14, 2023

    4

  • Dr. Sultan Al-Mutairi
    @sultanalazizi (Twitter)

    RT @drjoharji1: @TaibMoh12386758 دواء اوزمبيك في دراسة sustain 6 استطاع تقليل فرص حصول جلطات دماغية بنسبة ٣٩٪ مقارنة بالبلاسيبو https://t.c…
    view full post

    September 15, 2022

    1

  • د.عبدالرحمن جوهرجي
    @drjoharji1 (Twitter)

    @TaibMoh12386758 دواء اوزمبيك في دراسة sustain 6 استطاع تقليل فرص حصول جلطات دماغية بنسبة ٣٩٪ مقارنة بالبلاسيبو https://t.co/prt53Lkwmu + جرعة واحدة في الاسبوع + لايوجد خطورة هبوط في السكر + تحكم ممتاز في السكر
    view full post

    September 14, 2022

    9

    1

  • DJD
    @DJD81553730 (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    August 13, 2022

    100

  • Max Lugavere
    @maxlugavere (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    August 13, 2022

    100

  • DigestivoValdecilla
    @DigValdecilla (Twitter)

    RT @JhannaCueto: Se han publicados diferentes estudios mostrando la seguridad cardiovascular y prevención de eventos en población de riesgo…
    view full post

    August 7, 2022

    3

  • Jeffry Beltre E.
    @Mr_Jeffry (Twitter)

    RT @JhannaCueto: Se han publicados diferentes estudios mostrando la seguridad cardiovascular y prevención de eventos en población de riesgo…
    view full post

    August 6, 2022

    3

  • July
    @JulySeEs (Twitter)

    RT @JhannaCueto: Se han publicados diferentes estudios mostrando la seguridad cardiovascular y prevención de eventos en población de riesgo…
    view full post

    August 6, 2022

    3

  • Dra. Jhanna Cueto
    @JhannaCueto (Twitter)

    Se han publicados diferentes estudios mostrando la seguridad cardiovascular y prevención de eventos en población de riesgo
    view full post

    August 6, 2022

    1

    3

  • Sintayehu Abebe
    @sinta_gf (Twitter)

    RT @drscottyk: Another reason to prescribe GLP1’s: Sustain6 CV trial showed semaglutide (0.5 or 1 mg) reduced CV death, MI or stroke vs pl…
    view full post

    July 21, 2022

    5

  • Dr. Shashank Joshi
    @AskDrShashank (Twitter)

    RT @drscottyk: Another reason to prescribe GLP1’s: Sustain6 CV trial showed semaglutide (0.5 or 1 mg) reduced CV death, MI or stroke vs pl…
    view full post

    July 20, 2022

    5

  • Michael Buratovich
    @MichaelBuratovi (Twitter)

    RT @drscottyk: Another reason to prescribe GLP1’s: Sustain6 CV trial showed semaglutide (0.5 or 1 mg) reduced CV death, MI or stroke vs pl…
    view full post

    July 20, 2022

    5

  • tawfiq r choudhury
    @drtrc99 (Twitter)

    RT @drscottyk: Another reason to prescribe GLP1’s: Sustain6 CV trial showed semaglutide (0.5 or 1 mg) reduced CV death, MI or stroke vs pl…
    view full post

    July 20, 2022

    5

  • Dr Scott W Murray
    @DrScottMurray (Twitter)

    RT @drscottyk: Another reason to prescribe GLP1’s: Sustain6 CV trial showed semaglutide (0.5 or 1 mg) reduced CV death, MI or stroke vs pl…
    view full post

    July 20, 2022

    5

  • Scotty Kirkpatrick M.D.
    @drscottyk (Twitter)

    Another reason to prescribe GLP1’s: Sustain6 CV trial showed semaglutide (0.5 or 1 mg) reduced CV death, MI or stroke vs placebo (2.3% ARR, RR 26%, NNT 43) at 2 years in high risk patients with diabetes. https://t.co/mJH0ILTKh1
    view full post

    July 20, 2022

    16

    5

  • William Montaña
    @WilliamMontaa10 (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    June 28, 2022

    49

  • Nikola Crncevic
    @NikolaCrni179 (Twitter)

    RT @drscottyk: GLP1’s are incredible! The Sustain 6CV trial showed semaglutide (0.5 or 1 mg)⬇️CV death, MI or stroke vs placebo (2.3% ARR,…
    view full post

    June 23, 2022

    5

  • Raul Villar
    @DrRaulvillar (Twitter)

    RT @drscottyk: GLP1’s are incredible! The Sustain 6CV trial showed semaglutide (0.5 or 1 mg)⬇️CV death, MI or stroke vs placebo (2.3% ARR,…
    view full post

    June 22, 2022

    5

  • Akiva Rosenzveig
    @AkivaRosenzveig (Twitter)

    RT @drscottyk: GLP1’s are incredible! The Sustain 6CV trial showed semaglutide (0.5 or 1 mg)⬇️CV death, MI or stroke vs placebo (2.3% ARR,…
    view full post

    June 22, 2022

    5

  • Costas Tsakirides
    @tsakirides (Twitter)

    RT @drscottyk: GLP1’s are incredible! The Sustain 6CV trial showed semaglutide (0.5 or 1 mg)⬇️CV death, MI or stroke vs placebo (2.3% ARR,…
    view full post

    June 22, 2022

    5

  • Scotty Kirkpatrick M.D.
    @drscottyk (Twitter)

    GLP1’s are incredible! The Sustain 6CV trial showed semaglutide (0.5 or 1 mg)⬇️CV death, MI or stroke vs placebo (2.3% ARR, RR 26%, NNT 43) at 2yrs in ⬆️risk patients with DM. Looking forward to SELECT trial results (sema 2.4 mg CV outcome trial in⬆️BMI) https://t.co/mJH0ILTKh1
    view full post

    June 22, 2022

    14

    5

  • cardio-met
    @cardiomet_CE (Twitter)

    24c)
    view full post

    May 11, 2022

    2

  • The Cardiometabolic Forum
    @theCMforum (Twitter)

    Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. @NEJM 2019. View the summary here: https://t.co/JCHWGlF9IM
    view full post

    February 17, 2022

  • Endocrine dialogues
    @EndoDialogues (Twitter)

    It is still 2016 Less than 4 months after LEADER, SUSTAIN-6 comes. Semaglutide, another GLP-1 receptor agonist, shows to ⬇️ the composite outcome of stroke/myocardial infarction/cardiovascular death pts with T2D and⬆️ CV risk! SUSTAIN-6 https://t.co/J1YrLm0tb7 (8/13)
    view full post

    January 15, 2022

    14

  • David Macklin
    @DavidMacklinMD (Twitter)

    @MichaelAlbertMD
    view full post

    January 2, 2022

    1

  • syed shaban
    @SydShaban (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    December 2, 2021

    100

  • أ.د. وليد البكر
    @DrWaleedalbaker (Twitter)

    Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/lXeazVTECi
    view full post

    October 2, 2021

    1

  • Endocrine dialogues
    @EndoDialogues (Twitter)

    In many other studies, drugs proved to have the same impressive and unexpected benefits. https://t.co/TqtU2tjpJX https://t.co/Ff9utEIhxR
    view full post

    March 20, 2021

    2

  • Scott Morgans
    @Scott_Morgans1 (Twitter)

    Lots of people especially in the fitness industry up in arms, that medication isn’t the answer etc... However, semaglutide is showing real positive benefits around appetite suppression and its effects as a whole on CVD risk. https://t.co/iogIEvsHCS
    view full post

    February 20, 2021

  • Kausik
    @kausikdatta22 (Twitter)

    With me so far? Proper management of blood sugar—coupled with hunger suppression—is likely responsible for Semaglutide’s lowering of metabolic & heart risk factors (eg, blood pressure, HbA1c, cholesterol, triglycerides) + *secondary* weight loss effect. 7️⃣ https://t.co/DniDqLAFEy
    view full post

    February 18, 2021

  • Josh Beckman
    @JoshuaBeckmanMD (Twitter)

    @Plasmacellguy @Ultracardiodoc @skathire Well this is a good Rex for diabetes that reduces CV events, so I’m not sure what you are worried about. https://t.co/eWnxUG5vYr
    view full post

    February 11, 2021

    2

  • Dr. Spencer Nadolsky
    @DrNadolsky (Twitter)

    @KCKlatt @Hogwood_AC @ProfBatterhamMD @BrownAdey @KevinH_PhD @BioLayne Lower dose but CVD event benefit https://t.co/biZMQfFHrR
    view full post

    February 10, 2021

    6

  • benito Camela
    @carlosedu1819 (Twitter)

    Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Facebook:https://t.co/HMxlBrjB97 Youtube :https://t.co/SyUqiPCRv8
    view full post

    February 9, 2021

    6

  • Juan Senior
    @jsenior64 (Twitter)

    https://t.co/AhWtOdVpnY
    view full post

    January 11, 2021

  • Physician's Weekly
    @physicianswkly (Twitter)

    Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/GSD9U1Z0uq
    view full post

    August 18, 2020

  • Annyka
    @Annyka73458918 (Twitter)

    Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes , LINK VIDEO: https://t.co/1O9ekwufqw
    view full post

    July 28, 2020

  • Mohammed
    @_7M0DY_ (Twitter)

    https://t.co/YkPGSAzrF1
    view full post

    July 27, 2020

  • おだQ
    @OdaQ_DM (Twitter)

    GLP-1受容体作動薬の心血管エビデンス一覧2 ・リキセナチド（商品名リキスミア) ELIXA https://t.co/xuafQgvrFE ・セマグルチド(商品名オゼンピック) SUSTAIN 6 https://t.co/GbRauHohsf PIONEER 6(経口) https://t.co/DcznGmE55E ・アルビグルチド(日本非発売) HARMONY OUTCOMES
    view full post

    June 16, 2020

    15

    1

  • Stephan J. Guyenet
    @sguyenet (Twitter)

    @FrogHarmless Always possible. But to date, the most notable health-related side effect is a substantial reduction in cardiovascular event risk in people with T2DM. https://t.co/bJgJqI9ABh
    view full post

    May 14, 2020

    1

  • Fernand Bteich, MD, MS
    @fernandbteich (Twitter)

    9/ Weight loss was also prominent with semaglutide (as high as 6kg or 13lbs). Maximal effect on glycemia is reached ~10-16wks after starting treatment. Weight loss plateau is reached after ~10wks. N Engl J Med 2016; 375:1834-1844 DOI:10.1056/NEJMoa1607141 ⬇️ https://t.co/N66BMBNlJA
    view full post

    April 30, 2020

    3

  • GrupoCronosSEFH
    @GRUPOCRONOSSEF1 (Twitter)

    Para hoy jueves refrescamos este artículo del mes pasado de @NEJM Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Disponible en: https://t.co/g3CYDkWxeb
    view full post

    November 7, 2019

    1

  • 名前
    @akkiii0830 (Twitter)

    SUSTAIN6 CVOT https://t.co/HmqdU9w1ir
    view full post

    September 30, 2019

    1

  • Omid Hakami Hakami
    @Omidhakami (Twitter)

    RT @FarmaMadridAP: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes via @NEJM https://t.co/mjG7ikfb7r
    view full post

    September 25, 2019

    3

  • Salvador Rivera
    @salvarivera (Twitter)

    RT @FarmaMadridAP: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes via @NEJM https://t.co/mjG7ikfb7r
    view full post

    September 25, 2019

    3

  • Marcelo Mario Avellanal Leal
    @parreshia (Twitter)

    RT @FarmaMadridAP: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes via @NEJM https://t.co/mjG7ikfb7r
    view full post

    September 25, 2019

    3

  • Farmacia Madrid AP
    @FarmaMadridAP (Twitter)

    Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes via @NEJM https://t.co/mjG7ikfb7r
    view full post

    September 25, 2019

    2

    3

  • KristopherMaday PA-C
    @PA_Maday (Twitter)

    PIONEER 6 Trial Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/jLHVJMtbYb https://t.co/Zf65V5o7o8
    view full post

    September 23, 2019

  • Diego Peñailillo Güenante
    @nachX (Twitter)

    @JuanPeirano Los GLP1-RA tienen efecto demostrado de la disminución de MACE https://t.co/lNPaeOF8iT https://t.co/Mt9yLDpQlX
    view full post

    September 19, 2019

  • Anand. A Hardikar
    @AnandHardikar (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 11, 2019

    100

  • rodrigo zumbado
    @zumbadoMD (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 10, 2019

    100

  • Dr. Gilberto Pérez López MD PhD
    @Endocrino_PED (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 7, 2019

    49

  • Umar Shakur
    @u_shakur (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 6, 2019

    49

  • Teja naveen
    @tejanaveenbolem (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 5, 2019

    100

  • 散歩ミカン
    @sanpo_mikan (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 4, 2019

    49

  • 散歩ミカン
    @sanpo_mikan (Twitter)

    2型糖尿病患者における経口セマグルチドと心血管転帰 Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. M. Husain and Others. N Engl J Med 2019; 381:841-851. https://t.co/B8EiDYWyTd
    view full post

    September 4, 2019

    2

  • RODRIGO LUNA
    @RODRIGO32984659 (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 4, 2019

    49

  • orlando henne
    @ohenne2 (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 4, 2019

    49

  • leo uzych
    @LeoUzych (Twitter)

    Oral #Semaglutide and #Cardiovascular Outcomes in Patients with Type 2 #Diabetes | #NEJM https://t.co/5EyJmwKrxu
    view full post

    September 4, 2019

  • Dr.Marco Antonio C
    @drmarcocamacho (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 4, 2019

    49

  • María Antequera
    @mellitus_1 (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 4, 2019

    49

  • SaludHEALTHinfo
    @SaludHEALTHinfo (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 4, 2019

    49

  • María Ballesteros
    @mdballesteros (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 4, 2019

    49

  • Akif Acay
    @akifacay (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Leslie David, MD
    @Sportslad (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • PublicHealthMaps
    @PublicHealthMap (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Marina
    @Marina_nefro (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Ana Piera #JuntosEsMasFacil
    @ana_apiecar (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Iván
    @Dockat16 (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Stefania Arciello
    @StefaniaArciell (Twitter)

    Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/bQuSFrPUy0
    view full post

    September 3, 2019

  • ligiamendes
    @ligiamendes76 (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Manuel Beltrán
    @ManoloBeltranR (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Carlos
    @cavicae22 (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Cristobal Morales
    @CristobMorales (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Manuel Ruelas
    @ManuelRuelas21 (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Tu Endocrino
    @TuendocrinoSEEN (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • ( ノ´.ㅅ` )ノรางวัลที่ 1 มาแน่!!!
    @lexokkaz2 (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • J. Cena
    @DrJCena (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Medical Research Library of Brooklyn
    @DMCLibraryBKLYN (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Hanna Gaggin
    @HannaGaggin (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 3, 2019

    100

  • Smileyploi:D
    @Jpolyploid1 (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Dr.Yasser Alwali
    @DrYasserAlwali (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Unya S
    @UnyaS (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Yevgen Zolotarov
    @zolotarov (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 3, 2019

    100

  • Dr. Perez-Belmonte
    @belmonte_dr (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • FAM
    @alvmufa (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Rafael Aguilella
    @rafaelaguilella (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Dr. Karoki
    @Dr_karoki (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • APL
    @AndreaPestanaL (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Jose Ferreira Santos
    @japfs (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • 平社員
    @T462759 (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Don Epezilo
    @seinanathema (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • horottoilvetro
    @horottoilvetro (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • M Shafi Kuchay
    @drshafikuchay (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Pharmacy Updates
    @NaplexReviewQs (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Dr Jean Pierre Laroche #vacciné 6.0
    @Echoraljpangio (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Mafer
    @Mafer_XHP (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • Pub Health Monitor
    @monitor_PH (Twitter)

    RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…
    view full post

    September 3, 2019

    49

  • NEJM
    @NEJM (Twitter)

    #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.co/vfSvtmms4a
    view full post

    September 3, 2019

    76

    49

  • Michael Buratovich
    @MichaelBuratovi (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 2, 2019

    100

  • Mehroz Ehsan
    @mehrozehsan (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 2, 2019

    100

  • François Marchildon
    @FMarchildon (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 2, 2019

    100

  • Vladimir Heiskanen
    @ValtsuH (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 2, 2019

    100

  • Santito
    @SantitoBastardo (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 2, 2019

    100

  • Stephen Heitner
    @HeitnerStephen (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 2, 2019

    100

  • Dylan
    @sp6c3inv6d3r (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 2, 2019

    100

  • Paul Knoepfler
    @pknoepfler (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 2, 2019

    100

  • Jan Vyjidak
    @janvyjidak (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 2, 2019

    100

  • Biotech-Catalyst
    @BIOTECH888 (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 1, 2019

    100

  • Zahraddin Abdullahi
    @Xahraddin_A (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 1, 2019

    100

  • Matthew Theisen
    @RealTheisen (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 1, 2019

    100

  • Yanfei Zhang
    @zhyanfei123 (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 1, 2019

    100

  • Abhishek Kulkarni
    @AbhiKulk82 (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 1, 2019

    100

  • JUSTADUDE
    @mookiemanboi (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 1, 2019

    100

  • Jan Ehses
    @JanEhses (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 1, 2019

    100

  • Tune H. Pers
    @tunepers (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 1, 2019

    100

  • Raymond Francis Sarmiento, M.D.
    @rfrsarmiento (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 1, 2019

    100

  • George Thampy
    @GeorgeThampy (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 1, 2019

    100

  • George Dawson
    @dawso007 (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    September 1, 2019

    100

  • David Macklin
    @DavidMacklinMD (Twitter)

    @AnilMakam @VPrasadMDMPH Yet Anil we have many DM2 meds , but we have NO other diabetes medications that can, with behavioural support, generate a mean weight loss of 18+ percent at one year. And also with + Cardiovascular safety https://t.co/kBG0tLXkfo in non-inferiority study https://t.co/nQ9Sb4YgqL
    view full post

    August 31, 2019

  • Florian Wünnemann
    @flowuenne (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    August 31, 2019

    100

  • SY Investing
    @syinvesting (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    August 31, 2019

    100

  • subbakrishna rao
    @SubkrishnaRao (Twitter)

    RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…
    view full post

    August 31, 2019

    100

  • Neil Floch MD
    @NeilFlochMD (Twitter)

    RT @RpratleyMD: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/YKHeUdNFIT #ADA2019
    view full post

    June 19, 2019

    5

  • Ethical GmbH
    @Ethicalgmbh (Twitter)

    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/WTmOOp1kms
    view full post

    June 17, 2019

  • Viri diana
    @viridiana_dlt (Twitter)

    RT @RpratleyMD: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/YKHeUdNFIT #ADA2019
    view full post

    June 12, 2019

    5

  • Basem Mishriky, MD, FACP, ABOM Diplomate
    @BasemMishriky (Twitter)

    RT @RpratleyMD: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/YKHeUdNFIT #ADA2019
    view full post

    June 11, 2019

    5

  • Dr. Fermin Gonzalez
    @fermin98380786 (Twitter)

    RT @RpratleyMD: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/YKHeUdNFIT #ADA2019
    view full post

    June 11, 2019

    5

Abstract Synopsis

  • The study assessed the cardiovascular safety of semaglutide, a diabetes treatment, in type 2 diabetes patients over a 104-week period.
  • Among the 3297 participants, semaglutide users had a lower incidence of cardiovascular events compared to the placebo group, indicating potential cardiovascular benefits.
  • However, while semaglutide showed lower rates of kidney issues, it was associated with higher rates of retinopathy complications, highlighting a need for careful monitoring.